Phase II of the LAMOST-Kepler/K2 survey. I. Time series of medium-resolution spectroscopic observations

Phase \RNum{2} of the LAMOST-{\sl Kepler/K}2 survey (LK-MRS), initiated in 2018, aims at collecting medium-resolution spectra ($R\sim7,500$; hereafter MRS) for more than $50,000$ stars with multiple visits ($\sim60$ epochs) over a period of 5 years (2018 September to 2023 June). We selected 20 footprints distributed across the {\sl Kepler} field and six {\sl K}2 campaigns, with each plate containing a number of stars ranging from $\sim2,000$ to $\sim 3,000$. During the first year of observations, the LK-MRS has already collected $\sim280,000$ and $\sim369,000$ high-quality spectra in the blue and red wavelength range, respectively. The atmospheric parameters and radial velocities for $\sim259,000$ spectra of $21,053$ targets were successfully calculated by the LASP pipeline. The internal uncertainties for the effective temperature, surface gravity, metallicity, and radial velocity are found to be $100$\,K, $0.15$\,dex, $0.09$\,dex, and $1.00$\,km\,s$^{-1}$, respectively. We found $14,997$, $20,091$, and $1,514$ stars in common with the targets from the LAMOST low-resolution survey (LRS), GAIA and APOGEE, respectively, corresponding to a fraction of $\sim70\%$, $\sim95\%$ and $\sim7.2\%$. In general, the parameters derived from LK-MRS spectra are consistent with those obtained from the LRS and APOGEE spectra, but the scatter increases as the surface gravity decreases when comparing with the measurements from APOGEE. A large discrepancy is found with the GAIA values of the effective temperature. The comparisons of radial velocities of LK-MRS to GAIA and LK-MRS to APOGEE nearly follow an Gaussian distribution with a mean $\mu\sim1.10$ and $0.73$\,km\,s$^{-1}$, respectively.Comment: 24 pages, 15 figures, 4 tables, ApJS, accepte

Machine-learning based patient classification using Hepatitis B virus full-length genome quasispecies from Asian and European cohorts

Chronic infection with Hepatitis B virus (HBV) is a major risk factor for the development of advanced liver disease including fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). The relative contribution of virological factors to disease progression has not been fully defined and tools aiding the deconvolution of complex patient virus profiles is an unmet clinical need. Vari

Multicolor Combinatorial Probe Coding for Real-Time PCR

The target volume of multiplex real-time PCR assays is limited by the number of fluorescent dyes available and the number of fluorescence acquisition channels present in the PCR instrument. We hereby explored a probe labeling strategy that significantly increased the target volume of real-time PCR detection in one reaction. The labeling paradigm, termed “Multicolor Combinatorial Probe Coding” (MCPC), uses a limited number (n) of differently colored fluorophores in various combinations to label each probe, enabling one of 2n-1 genetic targets to be detected in one reaction. The proof-of-principle of MCPC was validated by identification of one of each possible 15 human papillomavirus types, which is the maximum target number theoretically detectable by MCPC with a 4-color channel instrument, in one reaction. MCPC was then improved from a one-primer-pair setting to a multiple-primer-pair format through Homo-Tag Assisted Non-Dimer (HAND) system to allow multiple primer pairs to be included in one reaction. This improvement was demonstrated via identification of one of the possible 10 foodborne pathogen candidates with 10 pairs of primers included in one reaction, which had limit of detection equivalent to the uniplex PCR. MCPC was further explored in detecting combined genotypes of five β-globin gene mutations where multiple targets were co-amplified. MCPC strategy could expand the scope of real-time PCR assays in applications which are unachievable by current labeling strategy

Performance of Detecting IgM Antibodies against Enterovirus 71 for Early Diagnosis

Enterovirus 71 (EV71) infection is more likely to induce severe complications and mortality than other enteroviruses. Methods for detection of IgM antibody against EV71 had been established for years, however, the performance of the methods in the very early diagnosis of EV71 infection had not been fully evaluated, which is especially meaningful because of the short incubation period of EV71 infection. In this report, the performance of an IgM anti-EV71 assay was evaluated using acute sera collected from 165 EV71 infected patients, 165 patients infected with other enteroviruses, and more than 2,000 sera from healthy children or children with other infected diseases. The results showed a 90% sensitivity in 20 patients who were in their first illness day, and similar sensitivity remained till 4 days after onset. After then the sensitivity increased to 95% to 100% for more than one month. The specificity of the assay in non-HFMD children is 99.1% (95% CI: 98.6–99.4), similar as the 99.9% specificity in healthy adults. The cross-reaction rate in patients infected with other non-EV71 enteroviruses was 11.4%. In conclusion, the data here presented show that the detection of IgM anti-EV71 by ELISA affords a reliable, convenient, and prompt diagnosis of EV71 infection

Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction, GALACTIC‐HF: baseline characteristics and comparison with contemporary clinical trials

Aims: The safety and efficacy of the novel selective cardiac myosin activator, omecamtiv mecarbil, in patients with heart failure with reduced ejection fraction (HFrEF) is tested in the Global Approach to Lowering Adverse Cardiac outcomes Through Improving Contractility in Heart Failure (GALACTIC‐HF) trial. Here we describe the baseline characteristics of participants in GALACTIC‐HF and how these compare with other contemporary trials. Methods and Results: Adults with established HFrEF, New York Heart Association functional class (NYHA) ≥ II, EF ≤35%, elevated natriuretic peptides and either current hospitalization for HF or history of hospitalization/ emergency department visit for HF within a year were randomized to either placebo or omecamtiv mecarbil (pharmacokinetic‐guided dosing: 25, 37.5 or 50 mg bid). 8256 patients [male (79%), non‐white (22%), mean age 65 years] were enrolled with a mean EF 27%, ischemic etiology in 54%, NYHA II 53% and III/IV 47%, and median NT‐proBNP 1971 pg/mL. HF therapies at baseline were among the most effectively employed in contemporary HF trials. GALACTIC‐HF randomized patients representative of recent HF registries and trials with substantial numbers of patients also having characteristics understudied in previous trials including more from North America (n = 1386), enrolled as inpatients (n = 2084), systolic blood pressure < 100 mmHg (n = 1127), estimated glomerular filtration rate < 30 mL/min/1.73 m2 (n = 528), and treated with sacubitril‐valsartan at baseline (n = 1594). Conclusions: GALACTIC‐HF enrolled a well‐treated, high‐risk population from both inpatient and outpatient settings, which will provide a definitive evaluation of the efficacy and safety of this novel therapy, as well as informing its potential future implementation

A novel immunoassay for PreS1 and/or core-related antigens for detection of HBsAg variants

A novel immunoassay that detects simultaneously hepatitis B virus (HBV) PreS1 and/or core-related antigens was developed and evaluated for its potential for detecting hepatitis B surface antigen (HBsAg) variants. The detection limits of the assay was 10(2.9 +/- 05) copies/mL (mean +/- SD) for HBsAg-positive sera with different genotypes, and 10(3.5 +/- 1.2) copies/mL for HBsAg variants sera. The specificity of the assay was 99.9% (95% Cl: 99.7-99.9%, 4551 healthy individuals). The sensitivities were 93.9% (95% Cl: 92.8-94.9%), 59.3% (95% Cl: 38.7-77.6%) and 80% (95% CI: 44.4-97.5%) in three independent groups which include: 2065 hepatitis patients, 27 patients with occult hepatitis B and 10 HBsAg variants, respectively. In addition, a novel premature stop code mutation at position 112 of HBsAg was observed in two patients with chronic hepatitis B with different genotypes. (C) 2010 Elsevier B.V. All rights reserved.National Advanced Technology Research and Development Program [2006AA02Z442, 2006AA020905]; Program for New Century Excellent Talents in University [NCET-05-0567